HomeAI · summaries
Storia in 5 fonti
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on…
- ·
forbes.com
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people lose nearly 56 pounds on average.
